Usefulness of HeberFERON® in patients with basal cell carcinoma
Keywords:
skin cancer, basal cell carcinoma, immunotherapy, HeberFERON®.Abstract
Introduction: The basal cell carcinoma is the most frequent epithelial neoplasm, because it constitutes 60-80 % of all the cutaneous cancers.
Objective: To determine the answer to HeberFERON® in patients with basal cell carcinoma.
Methods: An observational, descriptive and longitudinal study of 90 patients with basal cell carcinoma to whom HeberFERON® was administered was carried out at Dr. Juan Bruno Zayas Alfonso Teaching General Hospital in Santiago de Cuba, from January, 2017 to December, 2019. Some demographic, clinical variables that responded to the treatment were analyzed.
Results: The average age was 63 years; there was a higher incidence of the male sex (58 for 64.4 %) and the cutaneous fototype II (56 for 62.0 %), with lesions located in the nose (42 for 46.7 %), as well as a prevalence of the nodular clinical subtype (41 for 45.6 %). The control of the disease was achieved in 100.0 % of the case material.
Conclusions: The HeberFERON® was very useful in patients with basal cell carcinoma, since in more than a half of them a complete response was obtained, with a minimum of adverse events, all of them light and moderate.
Downloads
References
2. Wu PA. Epidemiology, pathogenesis, and clinical features of basal cell carcinoma. UpToDate. 2018 [citado 23/10/2019]. Disponible en: https://www.uptodate.com/contents/epidemiology-pathogenesis-and-clinical-features-of-basal-cell-carcinoma?search=epidemiology-pathogenesis-and-clinicalfeatures-of-basal-cell-carcinoma&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1
3. Rodríguez Fonseca RA, de la Rosa Santana JD, López Wilson A, Santiesteban Puerta S, Cabrera Pérez CR. Tratamiento con HeberFERON® en pacientes con carcinoma basocelular del Hospital Clínico Quirúrgico “Dr. Miguel Enríquez”, La Habana. 2018. Gac méd estud. 2020 [citado 20/12/2020]; 1 (2): 122-32. Disponible en: http://www.revgacetaestudiantil.sld.cu/index.php/gme/article/view/30
4. Cuba. Ministerio de Salud Pública. Anuario Estadístico de Salud. Dirección de Registros Médicos y Estadísticas de Salud 2017. La Habana: MINSAP; 2018 [citado 20/12/2020]. Disponible en: https://files.sld.cu/dne/files/2018/04/Anuario-Electronico-Espa%c3%b1ol-2017-ed-2018.pdf
5. Cabrera Naranjo DL, Sánchez Linares V, Román Simón M, Rondón Madrigal E, Bello Rivero I. Carcinoma basocelular tratado con HeberFERON, seguimiento clínico, histológico y ecográfico. Reporte de caso. Gac. Méd. Espirit. 2020 [citado 20/12/2020]; 22 (3): 119-28. Disponible en: https://www.medigraphic.com/pdfs/espirituana/gme-2020/gme203n.pdf
6. Álvarez Castillo A, Rodríguez Alfaro JM, Salas Boza A. Revisión sistemática del carcinoma basocelular. Rev.méd.sinerg. 2020 [citado 01/03/2020]; 5 (5): e483. Disponible en: https://revistamedicasinergia.com/index.php/rms/article/view/483
7. Álvarez Salafranca M, Ara M, Zaballos P. Dermatoscopia del carcinoma basocelular: revisión actualizada. Actas Dermosifiliogr. 2021 [citado 25/08/2021]; 112 (4): 330-8. Disponible en: https://www.actasdermo.org/es-dermatoscopia-del-carcinoma-basocelular-revision-articulo-S0001731020305147
8. Ariza S, Espinosa S, Naranjo M. Nonsurgical Therapies for Basal Cell Carcinoma: A Review. Actas Dermosifiliogr. 2017 [citado 23/12/2020] 108 (9): 809-17. Disponible en: https://www.actasdermo.org/es-nonsurgical-therapies-for-basal-cell-articulo-S1578219017302792
9. Bello Rivero I, Garcia Vega Y, Duncan Roberts Y, Vazquez Blomquistc D. HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment. Semin Oncol. 2018 [citado 23/12/2019]; 45 (1-2). Disponible en: https://pubmed.ncbi.nlm.nih.gov/30318081/
10. Santiesteban Aguilar N, Rosabal Fernández AM, Ferrer Rosabal LC. Caracterización clínica e histopatológica del carcinoma basocelular. Revdosdic. 2018 [citado 23/10/2019]; 1 (1): 37-47. Disponible en: http://revdosdic.sld.cu/index.php/revdosdic/article/view/6
11. Uribe CJ, Anaya KC, Céspedes AM, Otero CR, Prada DM, Rueda JP, et al. Carcinoma basocelular de piel en el área metropolitana de Bucaramanga, Colombia: una mirada epidemiológica. Rev Asoc Colomb Dermatol. 2018 [citado 23/10/2020]; 26 (1): 18-23. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/26/20
12. Kwasniak LA, Garcia Zuazaga J. Basal cell carcinoma: evidence-based medicine and review of treatment modalities. Int J Dermatol. 2011 [citado 23/10/2019]; 50 (6): 645-58. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21595656/
13. García Martínez S, Millares López R. Asociación de radiación ultravioleta, fototipo de piel e histopatología del cáncer no melanoma. 7mo Congreso Virtual Hispanoamericano de Anatomía Patológica. 2005 [citado 14/01/2019]. Disponible en: http://www.conganat.org/7congreso/pdf/271.pdf
14. Carucci JA, Leffell DJ, Pettersen JS. Carcinoma Basocelular. En: Lowell A, Goldsmith SI, Katz BA, Gilchrest AS, Paller DJ, Leffell KW. Fitzpatrick. Dermatología en Medicina General. 8 ed. España: Editorial Médica Panamericana; 2014. p. 1293-1301.
15. Sánchez Linares V, Cifuentes Suarez JP, Martínez Cuervo JJ, Román Simón M, Pérez García C, Bello Rivero I. Carcinoma basocelular del rostro tratado con HeberFERON. Gac. Méd. Espirit. 2019 [citado 23/01/2020] 21 (2): 87-97. Disponible en: http://revgmespirituana.sld.cu/index.php/gme/article/view/%201992/html
16. Negrín Caceres Y, Cabrera Romero AC, Cárdenas Monzón L, Ferrer Pérez A, Batista Hernández NE. Tratamiento del carcinoma basocelular periocular con una combinación sinérgica de interferones alpha2b y gamma. Rev. Mex. Oftalmol. 2018 [citado 10/12/2019]; 92 (3): 136-43. Disponible en: https://www.medigraphic.com/pdfs/revmexoft/rmo-2018/rmo183d.pdf
17. Kafle PA, Hamal D, Sahu S, Poudyal P, Sahu S. Clinico-pathological Analysis of Malignant Eyelid and Adnexal Tumors Presenting to a Tertiary Eye Hospital of Eastern Nepal. BJHS. 2020 [citado 31/10/2020]; 4 (3): 840-4. Disponible en: https://www.researchgate.net/publication/339294009_Clinico-pathological_Analysis_of_Malignant_Eyelid_and_Adnexal_Tumors_Presenting_to_a_Tertiary_Eye_Hospital_Of_Eastern_Nepal
18. Ferrá Torres TM, Sánchez Rodríguez ES, Ballester Caballero Y, Sallary Gutiérrez K. Caracterización de pacientes con carcinoma basocelular tratados con HeberFERON. Arch. méd. Camagüey. 2020 [citado 21/12/2020] 24 (2): e 7136. Disponible en: http://revistaamc.sld.cu/index.php/ amc/article/view/7136
19. Armas Morell L, Sotolongo Díaz D. Efectividad del HeberFERON en el tratamiento del carcinoma basocelular. Ciego de Ávila: Universidad de Ciencias Médicas; 2019.
20. Anasagasti Angulo L, Garcia Y, Collazo S, Jimenez Barban Y, Tijerino Arrieta E, Ballester Caballero Y, et al. HeberFERON, formulation based on IFNs alpha2b and gamma for the treatment of non-melanoma skin cancer. AMJ. 2017 [citado 23/12/2019]; 10 (6):509-15. Disponible en: https://www.researchgate.net/publication/318191920_HeberFERON_formulation_based_on_IFNs_alpha2b_and_gamma_for_the_treatment_of_non-melanoma_skin_cancer
Published
How to Cite
Issue
Section
License
All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.
![Secimed](/templates/images/secimed.png"){kind=small}
Guidelines for authors
